JPMorgan Chase & Co. Reaffirms Buy Rating for MorphoSys (MOR)
MorphoSys (ETR:MOR)‘s stock had its “buy” rating reissued by equities researchers at JPMorgan Chase & Co. in a note issued to investors on Tuesday. They currently have a price target on the stock.
A number of other research analysts also recently issued reports on MOR. Goldman Sachs Group set a €86.00 ($106.17) price target on MorphoSys and gave the company a “neutral” rating in a report on Thursday, March 8th. Commerzbank set a €98.00 ($120.99) price target on MorphoSys and gave the company a “buy” rating in a report on Monday. Deutsche Bank set a €94.00 ($116.05) price target on MorphoSys and gave the company a “buy” rating in a report on Monday. Royal Bank of Canada set a €57.00 ($70.37) price target on MorphoSys and gave the company a “sell” rating in a report on Wednesday, February 14th. Finally, Independent Research set a €93.00 ($114.81) price target on MorphoSys and gave the company a “buy” rating in a report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. MorphoSys currently has an average rating of “Hold” and a consensus price target of €84.02 ($103.73).
MorphoSys (ETR:MOR) opened at €85.95 ($106.11) on Tuesday. The stock has a market capitalization of $2,530.00 and a price-to-earnings ratio of -35.66. MorphoSys has a 1-year low of €49.63 ($61.27) and a 1-year high of €88.40 ($109.14).
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.